Heartbeam (BEAT)

Its platform is built around a proprietary method for capturing the heart’s electrical signals in three dimensions. From that data, HeartBeam’s software synthesizes information comparable to a 12-lead ECG, the standard diagnostic format widely used in cardiology. This approach is designed to address limitations of many portable or consumer ECG tools, which often record fewer leads and may provide less diagnostic context for certain cardiac events.

HeartBeam’s products target use cases such as remote assessment of chest pain, arrhythmia evaluation, and ongoing monitoring of people at risk of cardiovascular disease. By combining compact hardware with software-based signal reconstruction, the company aims to support faster clinical decision-making and reduce unnecessary visits while helping identify patients who need urgent care.

The company operates in a large and competitive digital health and cardiac monitoring market that includes established medical device manufacturers, wearable technology providers, and remote patient monitoring platforms. Its commercial prospects depend on regulatory progress, physician adoption, reimbursement pathways, clinical validation, and the ability to integrate its technology into existing healthcare workflows. HeartBeam’s common stock therefore represents exposure to a smaller medical device innovator working at the intersection of cardiology, remote care, and software-enabled diagnostics.